Search results for "2720 Hematology"

showing 10 items of 22 documents

Incidence of Stent Thrombosis after Endovascular Treatment of Iliofemoral or Caval Veins in Patients with the Postthrombotic Syndrome.

2019

Abstract Background Patients with postthrombotic syndrome (PTS) treated with stents are at risk of stent thrombosis (ST). The incidence of ST in the presence and absence of anticoagulation therapy (AT) is unknown. Risk factors are not well understood. Patients and Methods From the prospective Swiss Venous Stent registry, we conducted a subgroup analysis of 136 consecutive patients with PTS. Incidence of ST was estimated from duplex ultrasound or venography, and reported for the time on and off AT. Baseline, procedural, and follow-up data were evaluated to identify factors associated with ST. Results Median follow-up was 20 (interquartile range [IQR] 9–40) months. AT was stopped in 43 (32%) …

0301 basic medicineAdultMalemedicine.medical_specialty2720 HematologyVenographySubgroup analysis610 Medicine & healthVena Cava Inferior030204 cardiovascular system & hematologyIliac VeinPostthrombotic Syndrome03 medical and health sciences0302 clinical medicineFibrinolytic AgentsInterquartile rangeRisk FactorsmedicineAlloysHumansCumulative incidenceRegistries610 Medicine & healthStrokemedicine.diagnostic_testbusiness.industryIncidence (epidemiology)10031 Clinic for AngiologyIncidenceHazard ratioEndovascular ProceduresAnticoagulantsThrombosisHematologyPhlebographyFemoral VeinMiddle Agedmedicine.diseaseConfidence intervalSurgery030104 developmental biologyTreatment OutcomeFemaleStentsbusinessSwitzerlandFollow-Up StudiesThrombosis and haemostasis
researchProduct

Aberrant splicing of the tumor suppressor CYLD promotes the development of chronic lymphocytic leukemia via sustained NF-κB signaling

2017

The pathogenesis of chronic lymphocytic leukemia (CLL) has been linked to constitutive NF-κB activation but the underlying mechanisms are poorly understood. Here we show that alternative splicing of the negative regulator of NF-κB and tumor suppressor gene CYLD regulates the pool of CD5+ B cells through sustained canonical NF-κB signaling. Reinforced canonical NF-κB activity leads to the development of B1 cell-associated tumor formation in aging mice by promoting survival and proliferation of CD5+ B cells, highly reminiscent of human B-CLL. We show that a substantial number of CLL patient samples express sCYLD, strongly implicating a role for it in human B-CLL. We propose that our new CLL-l…

0301 basic medicineCancer ResearchTumor suppressor geneCell SurvivalRNA SplicingChronic lymphocytic leukemia2720 Hematology610 Medicine & healthBiologyCD5 Antigenslaw.inventionPathogenesisMice03 medical and health sciencesimmune system diseaseslawhemic and lymphatic diseasesmedicineAnimalsHumans10239 Institute of Laboratory Animal Science1306 Cancer ResearchGenes Tumor SuppressorGeneCell ProliferationB-LymphocytesAlternative splicingNF-kappa BUbiquitinationHematologymedicine.diseaseLeukemia Lymphocytic Chronic B-CellDeubiquitinating Enzyme CYLDLeukemia030104 developmental biologyOncologyImmunologyCancer research570 Life sciences; biologySuppressor2730 OncologyCD5Signal TransductionLeukemia
researchProduct

Changing the education paradigm in oncology: ESO masterclass, 17 years of continuous success

2020

In this review, we summarize the history of the 41 Masterclasses in Clinical Oncology (MCO) organized by ESO or ESO-ESMO during the last 17 years. MCOs have been held in five different geographical regions including: a) Central Europe, b) Eastern Europe and Balkans, c) Baltic and Euroasia, d) Arab World and Southern European Countries and e) Latin America. More than 2.000 young oncologists have attended and more than 250 distinguished faculty members have actively participated. The program exposes students to sessions covering all major tumors ("big killers") and to spotlights updating information on various important cancers and related topics. Participants are able to present their own cl…

0301 basic medicineLatin Americans2720 HematologyLearning assessment610 Medicine & healthMedical Oncology03 medical and health sciences0302 clinical medicineSurveys and QuestionnairesMedicineTumor boardHumansSocieties MedicalClinical OncologyOncologistsMedical educationbusiness.industryTeachingHematologyTest (assessment)Europe030104 developmental biologyOncologyEducation Medical Graduate030220 oncology & carcinogenesis10032 Clinic for Oncology and Hematology2730 OncologyClinical casebusiness
researchProduct

Melanoma of unknown primary: New perspectives for an old story

2021

Melanoma of unknown primary site (MUP) comprises 3-4 % of all melanomas. It mostly presents in lymph nodes (LNs), followed by subcutaneous sites, and visceral organs; nevertheless, there is a trend of increase in the relative incidence of visceral counterpart in recent years. Spontaneous regression of the primary lesion is a well-established theory, based on the evidence that melanoma can undergo regression at the primary site. MUP and stage-matched melanoma of known primary site (MKP) share similar prognostic factors. The survival rate of patients with MUP has been compared to those with stage-matched MKP. Multiple studies conducted before the era of novel therapy with immune checkpoint or…

0301 basic medicineOncologymedicine.medical_specialtymedicine.medical_treatment2720 Hematology610 Medicine & healthTargeted therapy03 medical and health sciences0302 clinical medicineInternal medicineEpidemiologymedicineHumansMelanomaSurvival rateHematologybusiness.industryIncidenceMelanomaIncidence (epidemiology)General MedicineHematologyImmunotherapymedicine.disease10174 Clinic for GynecologyImmune checkpointSurvival Rate030104 developmental biologyOncology030220 oncology & carcinogenesisNeoplasms Unknown Primary2730 OncologyLymph NodesGeriatrics and GerontologybusinessCritical Reviews in Oncology/Hematology
researchProduct

The Millennial Generation of Thrombosis and Hemostasis

2020

2019-20 coronavirus outbreakHemostasisCoronavirus disease 2019 (COVID-19)business.industry10031 Clinic for AngiologySevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)2720 Hematology610 Medicine & healthThrombosisHematologyBioinformaticsmedicine.diseaseThrombosisHemostasisMedicineHumansbusinessHämostaseologie
researchProduct

Course of D-Dimer and C-Reactive Protein Levels in Survivors and Nonsurvivors with COVID-19 Pneumonia: A Retrospective Analysis of 577 Patients

2020

2019-20 coronavirus outbreakmedicine.medical_specialtyCoronavirus disease 2019 (COVID-19)biologybusiness.industrySevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)10031 Clinic for AngiologyC-reactive protein2720 Hematology610 Medicine & healthHematologymedicine.diseasePneumoniaInternal medicineD-dimerbiology.proteinRetrospective analysisMedicinebusinessLetter to the EditorThrombosis and Haemostasis
researchProduct

Induction of B-cell development in adult mice reveals the ability of bone marrow to produce B-1a cells

2009

AbstractTo study B-cell development from bone marrow (BM), we generated recombination-activating gene 1 (Rag1)–targeted mice lacking mature lymphocytes. B-cell development can be induced in such mice by B cell–specific restoration of a functional Rag1 transcription unit. Follicular and marginal zone B cells populated the spleen when Rag1 expression was permitted. Notably, the peritoneal cavity was dominated by bona fide B-1a cells, as judged by surface markers and functional properties. These BM-derived B-1a cells exhibited a polyclonal VDJ repertoire with substantial N nucleotide insertions. Nevertheless, physiologic frequencies of phosphatidylcholine-specific B cells were detected. Import…

Adoptive cell transfer1303 BiochemistryGenes RAG-1Immunology2720 HematologyB-Lymphocyte SubsetsSpleenBone Marrow CellsEnzyme-Linked Immunosorbent AssayMice Transgenic610 Medicine & healthBiology10263 Institute of Experimental ImmunologyBiochemistryPolymerase Chain ReactionRecombination-activating gene1307 Cell BiologyPeritoneal cavityMicemedicineAnimalsB cellB-Lymphocytes2403 ImmunologyStem CellsCell DifferentiationCell BiologyHematologyMarginal zoneFlow CytometryMolecular biologyAdoptive Transfermedicine.anatomical_structureImmunoglobulin MImmunologybiology.protein570 Life sciences; biologyBone marrow
researchProduct

Anticoagulation in splanchnic and cerebral vein thrombosis: Still groping in the dark.

2020

Cerebral veinsmedicine.medical_specialtybusiness.industrymedicine.drug_classSplanchnic Circulation10031 Clinic for Angiology2720 HematologyAnticoagulantanticoagulantvenous thromboembolism610 Medicine & healthHematologyCerebral vein thrombosisbleedingcerebral veinsplanchnic circulationsInternal medicineCardiologyCommentaryMedicineDiseases of the blood and blood-forming organsRC633-647.5businessSplanchnicVenous thromboembolismResearch and practice in thrombosis and haemostasis
researchProduct

Sex-specific differences in chronic thromboembolic pulmonary hypertension. Results from the European CTEPH registry

2019

BACKGROUND: Women are more susceptible than men to several forms of pulmonary hypertension, but have better survival. Sparse data are available on chronic thromboembolic pulmonary hypertension (CTEPH). METHODS: We investigated sex-specific differences in the clinical presentation of CTEPH, performance of pulmonary endarterectomy (PEA), and survival. RESULTS: Women constituted one-half of the study population of the European CTEPH registry (N = 679) and were characterized by a lower prevalence of some cardiovascular risk factors, including prior acute coronary syndrome, smoking habit, and chronic obstructive pulmonary disease, but more prevalent obesity, cancer, and thyroid diseases. The med…

Malecardiovascular risk factorsAcute coronary syndromemedicine.medical_specialtyHypertension Pulmonary2720 Hematologypulmonary endarterectomyvenous thromboembolism610 MedizinChronic thromboembolic pulmonary hypertension610 Medicine & healthEndarterectomy030204 cardiovascular system & hematologyPulmonary Arterysurvivalchronic thromboembolic pulmonary hypertension03 medical and health sciencesPulmonary Disease Chronic Obstructive0302 clinical medicineInterquartile rangeInternal medicine610 Medical sciencesmedicineHumanssexRegistriesbusiness.industry10031 Clinic for AngiologyHazard ratioHematologyMiddle Agedmedicine.diseasePulmonary hypertensionObesityConfidence intervalmedicine.anatomical_structureChronic DiseasePopulation studyFemalebusinessPulmonary EmbolismArtery
researchProduct

Venous thromboembolism in patients hospitalized for hip joint replacement surgery

2020

Venous thromboembolism (VTE) is a potentially life-threatening disease. Major transient risk factors include trauma, surgery, and immobilization. Patients undergoing hip joint replacement (HJR) are characterized by a high risk of postoperative VTE, but data on the time trends of VTE rates in this population are sparse.In an analysis of the German nationwide inpatient sample, we included all hospitalizations for elective primary HJR in Germany from 2005 to 2016. Time trends of the surgical procedure, overall death rates, and VTE rates were analysed, and predictors of VTE identified.Overall, 1,885,839 inpatients with elective primary HJR (59.1% women, 51.4% ≥70 years) were included in the ana…

Malemedicine.medical_specialtyArthroplasty Replacement HipPopulation2720 Hematology610 Medicine & healthDisease030204 cardiovascular system & hematology03 medical and health sciences0302 clinical medicineRisk FactorsHip replacementGermanymedicineHumanscardiovascular diseasesHospital Mortalityeducationeducation.field_of_studybusiness.industryMortality rate10031 Clinic for AngiologyCancerPerioperativeVenous ThromboembolismHematologyequipment and suppliesmedicine.diseaseSurgeryPulmonary embolismHospitalization030220 oncology & carcinogenesisFemalebusinessVenous thromboembolism
researchProduct